Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
ACS Chemical Neuroscience|August 30, 2018
Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional ConversionSamuel Obeng, Huiqun Wang, Abdulmajeed Jali, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 24, 2015
Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse ForebrainMatthew F Lazenka, Aaron J Tomarchio, Aron H Lichtman, et al.
Journal of Neurochemistry|May 22, 2001
Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activationD E Selley, W K Rorrer, C S Breivogel, et al.
Organic & Biomolecular Chemistry|February 23, 2012
Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5Yunyun Yuan, Christopher K Arnatt, Guo Li, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 7, 2008
N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipaseJames J Burston, Laura J Sim-Selley, John P Harloe, et al.
Bioorganic & Medicinal Chemistry|October 15, 2010
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptorJohn W Huffman, Seon A Hepburn, Nataliya Lyutenko, et al.
Brain Research|April 13, 2010
Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of miceMichelle R Hoot, Laura J Sim-Selley, Justin L Poklis, et al.
ACS Chemical Neuroscience|July 13, 2018
Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor ModulatorsYi Zheng, Samuel Obeng, Huiqun Wang, et al.
Neurobiology of Disease|February 5, 2016
Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrainYun K Hahn, Jason J Paris, Aron H Lichtman, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2021
Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and CannabinoidsD E Selley, M L Banks, C M Diester, et al.
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
ACS Chemical Neuroscience|August 30, 2018
Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional ConversionSamuel Obeng, Huiqun Wang, Abdulmajeed Jali, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 24, 2015
Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse ForebrainMatthew F Lazenka, Aaron J Tomarchio, Aron H Lichtman, et al.
Journal of Neurochemistry|May 22, 2001
Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activationD E Selley, W K Rorrer, C S Breivogel, et al.
Organic & Biomolecular Chemistry|February 23, 2012
Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5Yunyun Yuan, Christopher K Arnatt, Guo Li, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 7, 2008
N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipaseJames J Burston, Laura J Sim-Selley, John P Harloe, et al.
Bioorganic & Medicinal Chemistry|October 15, 2010
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptorJohn W Huffman, Seon A Hepburn, Nataliya Lyutenko, et al.
Brain Research|April 13, 2010
Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of miceMichelle R Hoot, Laura J Sim-Selley, Justin L Poklis, et al.
ACS Chemical Neuroscience|July 13, 2018
Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor ModulatorsYi Zheng, Samuel Obeng, Huiqun Wang, et al.
Neurobiology of Disease|February 5, 2016
Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrainYun K Hahn, Jason J Paris, Aron H Lichtman, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2021
Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and CannabinoidsD E Selley, M L Banks, C M Diester, et al.
Pageof 15